Tenecteplase demonstrated significantly higher early successful recanalization rates in distal and medium vessel occlusion strokes compared to alteplase.
Patients treated with tenecteplase experienced notably less substantial early infarct growth, indicating potential neuroprotective benefits.
The study supports tenecteplase as a preferable intravenous thrombolytic agent in DMVO strokes where endovascular thrombectomy is not pursued.
